Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors
Mellgard G, Patel V, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher E, Oh W, Galsky M, Tsao C. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. Journal Of Cancer Research And Clinical Oncology 2022, 149: 2833-2841. PMID: 35788726, PMCID: PMC10739778, DOI: 10.1007/s00432-022-04159-y.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeClinical activity of immune checkpoint blockadeAdvanced solid tumorsOverall survivalT cell activationClinical outcomesSolid tumorsCD8+ T cell activationClinical activityClinical outcomes of patientsAdrenergic signalingAntitumor immune activityPharmacological beta-blockadeUrothelial carcinoma cohortImmune checkpoint inhibitorsInfluence overall survivalCox proportional hazards regression modelsDuration of therapyAssociation of OSOutcomes of patientsBeta-blocker useDisease control statusProportional hazards regression modelsBeta-adrenergic signalingInhibited tumor growth
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply